Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504619 · ClinicalTrials.gov registry record · Phase 1
Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
A Phase 1 study, sponsored by Gamida Cell.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02504619: Clinical Trial Phase 1 study, sponsored by Gamida Cell.
NCT02504619 is a Phase 1 study that was terminated before completion, run by Gamida Cell. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02504619, a Phase 1 study, was terminated before completion, sponsored by Gamida Cell.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.
Primary Outcome
The number of patients with grade 4 or 5 toxicity were estimated together with 95% confidence limits based on the binomial distribution. The proportion with toxicity grades 1, 2, and 3 was also estimated.
Interventions
- BIOLOGICAL CordIn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Why NCT02504619 stopped before completion
NCT02504619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which CordIn is the first listed.
NCT02504619 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02504619 about?
NCT02504619 is a clinical study titled "Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies". CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.
What is the current status of trial NCT02504619?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2016-04-04. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02504619?
The interventions under investigation include: CordIn (BIOLOGICAL).
Who is sponsoring clinical trial NCT02504619?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02504619's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI